NK Cells Adjuvant Therapy Reveals Obvious Survival Benefits in a Gastric Mixed Signet Ring Cell Carcinoma Patient: A Case Report

Abstract Background: Advanced signet ring cell (SRC) carcinoma has a worse prognosis. Therefore, early diagnosis and prevention is particularly important; SRC tumours have lower R0 resection rate and are thought to be less chemosensitive than non-SRCC. Consequently, a novel postoperative adjuvant treatment is urgently needed to improve clinical outcomes.Case presentation: A 41-year-old female with paroxysmal vomiting for more than one year come to hospital for gastroscopy examination in 2015. The gastroscopy revealed signet ring cell carcinoma of gastric antrum and poorly differentiated adenocarcinoma in some areas. The patient was treated with radical gastrectomy for gastric cancer and oxaliplatin-based regimen for 6 cycles after surgery. Natural killer (NK) cells immunotherapy was started after November 2016, three times a year, up to now, no suspicious lesions were evident, and the levels of serum tumor markers were normal.Conclusions: Intravenous injections of NK cells combination with surgical treatment and chemotherapy showed therapeutic effects in this patient with possible relapse.

Download Full-text

NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient

Medicine ◽

10.1097/md.0000000000024979 ◽

2021 ◽

Vol 100 (10) ◽

pp. e24979

Author(s):

Yuan-Yuan Jin ◽

Wen-Zhuo Yang ◽

Zheng-Yang Sun ◽

Zhong-Bo Wang ◽

Jian Chen ◽

...

Keyword(s):

Adjuvant Therapy ◽

Cell Carcinoma ◽

Nk Cells ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Carcinoma Patient ◽

Signet Ring ◽

Ring Cell

Download Full-text

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

10.21203/rs.3.rs-53988/v1 ◽

2020 ◽

Author(s):

Akihiko Takagi ◽

Satoshi Tokuda ◽

Takeo Toda ◽

Kazuya Higashizono ◽

Keisei Taku ◽

...

Keyword(s):

Adjuvant Chemotherapy ◽

Portal Vein ◽

Cell Carcinoma ◽

Signet Ring Cell Carcinoma ◽

Good Prognosis ◽

Signet Ring Cell ◽

Term Survival ◽

Signet Ring ◽

Ring Cell ◽

One Year

Abstract Background: Signet ring cell carcinoma (SRCC) of the pancreas is a very rare histologic variant of pancreatic carcinoma with very poor prognosis. We present a case of pancreatic SRCC with good prognosis achieved by resection and adjuvant chemotherapy with S-1 one year, which is the standard treatment for advanced resected gastric cancer in Japan. The stomach carried a higher incidence of SRCC than other sites.Case presentation: A 70-year-old man presented with abdominal discomfort, and ultrasonography revealed a mass in the pancreas. Computed tomography showed a hypovascular tumor in the head of the pancreas, 51 mm in diameter, with invasion to the portal vein and duodenum. The patient underwent pancreaticoduodenectomy (PD) with portal vein resection and reconstruction. The pathological diagnosis was SRCC of the pancreas without invasion to the portal vein, pT3N1M0 Stage IIB (UICC classification). Subsequently, postoperative adjuvant chemotherapy with S-1 was initiated to prevent recurrence. The patient has remained recurrence-free for 2 years and 6 months after PD. Conclusion: Adjuvant chemotherapy with S-1 may be an important factor for improving the prognosis of patients with resectable SRCC of the pancreas.

Download Full-text

Signet ring cell carcinoma of the ampulla of Vater

10.26226/morressier.578f37fad462b8028d88fdf7 ◽

2016 ◽

Author(s):

Nihed Abdessayed

Keyword(s):

Cell Carcinoma ◽

Ampulla Of Vater ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Signet Ring ◽

Ring Cell

Download Full-text

Primary signet‐ring cell carcinoma of the lung in an HIV‐positive patient

Thoracic Cancer ◽

10.1111/1759-7714.13887 ◽

2021 ◽

Vol 12 (7) ◽

pp. 1122-1125

Author(s):

Alberto Testori ◽

Gianluca Perroni ◽

Camilla De Carlo ◽

Alessandro Crepaldi ◽

Marco Alloisio ◽

...

Keyword(s):

Cell Carcinoma ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Positive Patient ◽

Hiv Positive ◽

Signet Ring ◽

Ring Cell

Download Full-text

Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents

Current Oncology ◽

10.3390/curroncol28010090 ◽

2021 ◽

Vol 28 (1) ◽

pp. 918-927

Author(s):

Lei-Chi Wang ◽

Tai-Chi Lin ◽

Yi-Chen Yeh ◽

Hsiang-Ling Ho ◽

Chieh-Chih Tsai ◽

...

Keyword(s):

Next Generation Sequencing ◽

Cell Carcinoma ◽

Tumor Tissue ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Next Generation ◽

Signet Ring ◽

Ring Cell ◽

Generation Sequencing ◽

E Cadherin

Primary signet ring cell/histiocytoid carcinoma of the eyelid is a rare ocular malignancy and its diagnosis is often delayed. This neoplasm presents as an insidious, diffusely infiltrative mass in the periocular area that later infiltrates the orbit. An exenteration is usually indicated; however, nearly one-third of patients develop local recurrence or metastasis. Morphologically, it resembles signet ring cell carcinoma of the stomach and breast, raising the possibility of mutations in CDH1, the gene encoding E-cadherin. To determine whether primary signet ring cell/histiocytoid carcinoma harbors the CDH1 mutation or other actionable mutations, we analyzed the tumor tissue via next-generation sequencing. We identified only one case of primary signet ring cell carcinoma of the eyelid with adequate DNA quality for sequencing from the pathological archive during the period 2000 to 2020. A comprehensive evaluation including histopathology, immunohistochemistry, and next-generation sequencing assay was performed on tumor tissue. Immunohistochemically, the tumor exhibited E-cadherin membranous staining with the aberrant cytoplasmic staining of β-catenin. Using next-generation sequencing, we demonstrated the mutation in the CDH1 gene. In addition, other clinically actionable mutations including ERBB2 and PIK3CA were also detected. The alterations in other actionable genes indicate a need for larger studies to evaluate the pathogenesis and potential therapies for primary signet ring cell/histiocytoid carcinoma of the eyelid.

Download Full-text

Fundic Gland Polyp With Parietal Cell Vacuolation Mimicking Signet Ring Cell Carcinoma

International Journal of Surgical Pathology ◽

10.1177/1066896921994183 ◽

2021 ◽

pp. 106689692199418

Author(s):

John D. Coyne ◽

S. Thampy

Keyword(s):

Proton Pump Inhibitor ◽

Cell Carcinoma ◽

Parietal Cell ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Fundic Gland ◽

Fundic Gland Polyp ◽

Signet Ring ◽

Ring Cell

Pseudo-signet ring parietal cell vacuolation has been described as a mimic of invasive signet ring cell carcinoma. Moreover, signet ring cell carcinoma has been described in a fundic gland polyp. This case demonstrates parietal cell vacuolation in a fundic gland polyp in a patient on a long-term proton pump inhibitor.

Download Full-text

Protein profiling reveals the characteristic changes of the complement cascade pathway in the tissues of gastric signet ring cell carcinoma

Molecular & Cellular Proteomics ◽

10.1016/j.mcpro.2021.100068 ◽

2021 ◽

pp. 100068

Author(s):

Yang Fan ◽

Bin Bai ◽

Yuting Liang ◽

Yan Ren ◽

Yanxia Liu ◽

...

Keyword(s):

Cell Carcinoma ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Protein Profiling ◽

Complement Cascade ◽

Signet Ring ◽

Ring Cell

Download Full-text

A Signet Ring Cell Carcinoma Presented as Refractory Acquired Thrombotic Thrombocytopenic Purpura

Case Reports in Oncology ◽

10.1159/000510745 ◽

2020 ◽

Vol 13 (3) ◽

pp. 1368-1372

Author(s):

Umit Yavuz Malkan ◽

Murat Albayrak ◽

Hacer Berna Ozturk ◽

Merih Reis Aras ◽

Bugra Saglam ◽

...

Keyword(s):

Cell Carcinoma ◽

Plasma Exchange ◽

Thrombotic Thrombocytopenic Purpura ◽

Unknown Origin ◽

Signet Ring Cell Carcinoma ◽

Signet Ring Cell ◽

Thrombocytopenic Purpura ◽

Signet Ring ◽

Gastric Endoscopy ◽

Ring Cell

Microangiopathic hemolytic anemia (MAHA) can be observed as a paraneoplastic syndrome (PS) in certain tumors. MAHA-related signet ring cell carcinoma (SRCC) of an unknown origin is very infrequent. Herein we present a SRCC case presented with refractory acquired thrombotic thrombocytopenic purpura (TTP). A 35-year-old man applied to the emergency service with fatigue and headache. His laboratory tests resulted as white blood cell 9,020/µL, hemoglobin 3.5 g/dL, platelet 18,000/µL. Schistocytes, micro-spherocytes, and thrombocytopenia were observed in his blood smear. MAHA was present and he was considered as having TTP. Plasma exchange treatment was initiated; however, he was refractory to this treatment. Thorax and abdomen computerized tomography revealed thickening of minor curvature in stomach corpus with hepatogastric and paraceliac lymphadenopathy. Bone marrow (BM) investigation by our clinic resulted as the metastasis of adenocarcinoma. Ulceration and necrosis were observed by gastric endoscopy procedure. Biopsy was taken during endoscopic intervention, which resulted as SRCC. MAHA may be seen as a PS in some tumors, especially gastric cancers. Tumor-related MAHA is generally accompanied by BM metastases. As a result, BM investigation may be used as the main diagnostic method to find the underlying cancer. The clinical course of cases with tumor-related MAHA is usually poor, and these cases are usually refractory to plasma exchange treatment. In conclusion, physicians should suspect a malignancy and BM involvement when faced with a case of refractory TTP.

Download Full-text